Sai Life Sciences - Public Comps and Valuation Multiples

Sai Life Sciences Overview

About Sai Life Sciences

Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.

Founded

1999

HQ

Employees

3.4K+

Website

sailife.com

Sectors

Contract Research & Manufacturing
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $218M

LTM EBITDA $54.1M

EV

$2.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sai Life Sciences Financials

As of September 2025, Sai Life Sciences reported last 12-month revenue of $218M and EBITDA of $54.1M.

In the same period, Sai Life Sciences generated $158M in LTM gross profit and $25.7M in net income.

See Sai Life Sciences valuation multiples based on analyst estimates

Sai Life Sciences P&L

In the most recent fiscal year, Sai Life Sciences reported revenue of $189M and EBITDA of $50.3M.

Sai Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sai Life Sciences valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$218M	XXX	$189M	XXX	XXX	XXX
Gross Profit	$158M	XXX	$70.3M	XXX	XXX	XXX
Gross Margin	72%	XXX	37%	XXX	XXX	XXX
EBITDA	$54.1M	XXX	$50.3M	XXX	XXX	XXX
EBITDA Margin	25%	XXX	27%	XXX	XXX	XXX
EBIT	$37.6M	XXX	$31.0M	XXX	XXX	XXX
EBIT Margin	17%	XXX	16%	XXX	XXX	XXX
Net Profit	$25.7M	XXX	$19.3M	XXX	XXX	XXX
Net Margin	12%	XXX	10%	XXX	XXX	XXX
Net Debt	XXX	XXX	$4.3M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sai Life Sciences including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $218M. EBITDA for the last twelve months was $54.1M. In the most recent fiscal year, Sai Life Sciences achieved $189M in revenue and $50.3M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$218M	Analyst estimates available to subscribers	$189M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$158M	Analyst estimates available to subscribers	$70.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	72.1% gross margin	Analyst estimates available to subscribers	37.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$54.1M	Analyst estimates available to subscribers	$50.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	24.8% EBITDA margin	Analyst estimates available to subscribers	26.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$37.6M	Analyst estimates available to subscribers	$31.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	17.2% EBIT margin	Analyst estimates available to subscribers	16.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$25.7M	Analyst estimates available to subscribers	$19.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.8% net profit margin	Analyst estimates available to subscribers	10.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$4.3M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sai Life Sciences

This financial data table provides comprehensive performance metrics for Sai Life Sciences, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Sai Life Sciences generated $218M in revenue over the last twelve months.
The company achieved $54.1M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $158M.
Net income over the last twelve months reached $25.7M.

Fiscal Year Performance

In the most recent fiscal year, Sai Life Sciences reported $189M in total revenue.
Fiscal year EBITDA was $50.3M.
The company maintained a gross profit margin of 37.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 26.6%.
Net profit margin reached 10.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sai Life Sciences. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sai Life Sciences Stock Performance

Sai Life Sciences has current market cap of INR 189B (or $2.1B), and EV of INR 188B (or $2.1B).

Market Cap Evolution

Sai Life Sciences Stock Data

As of October 29, 2025, Sai Life Sciences's stock price is INR 898 (or $10).

See Sai Life Sciences trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.1B	$2.1B	XXX	XXX	XXX	XXX	$0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sai Life Sciences Valuation Multiples

Sai Life Sciences's trades at 11.7x EV/Revenue multiple, and 45.9x EV/EBITDA.

See valuation multiples for Sai Life Sciences and 15K+ public comps

Sai Life Sciences Financial Valuation Multiples

As of October 29, 2025, Sai Life Sciences has market cap of $2.1B and EV of $2.1B.

Equity research analysts estimate Sai Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sai Life Sciences has a P/E ratio of 83.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV/Revenue	9.8x	XXX	11.7x	XXX	XXX	XXX
EV/EBITDA	39.5x	XXX	45.9x	XXX	XXX	XXX
EV/EBIT	56.9x	XXX	75.3x	XXX	XXX	XXX
EV/Gross Profit	13.6x	XXX	n/a	XXX	XXX	XXX
P/E	83.4x	XXX	127.2x	XXX	XXX	XXX
EV/FCF	-51.7x	XXX	-893.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sai Life Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sai Life Sciences Margins & Growth Rates

Sai Life Sciences's last 12 month revenue growth is 20%

Sai Life Sciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $12K for the same period.

Sai Life Sciences's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sai Life Sciences's rule of X is 74% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sai Life Sciences and other 15K+ public comps

Sai Life Sciences Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	20%	XXX	21%	XXX	XXX	XXX
EBITDA Margin	25%	XXX	25%	XXX	XXX	XXX
EBITDA Growth	28%	XXX	24%	XXX	XXX	XXX
Rule of 40	45%	XXX	45%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	74%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$12K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	21%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial